Genomic signatures of breast cancer metastasis.
Despite significant advances in the treatment of primary cancer, the ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and they predict individual outcomes poorly. However, the recent introduction of high-throughput microarray technology has opened new avenues in genomic investigation of cancer, and through application in tissue-based studies and appropriate animal models, has facilitated the identification of gene expression signatures that are associated with the lethal progression of breast cancer. The use of these approaches has the potential to greatly impact our knowledge of tumor biology, to provide efficient biomarkers, and enable development towards customized prognostication and therapies for the individual.
Urquidi
V
V
Department of Medicine, University of Florida, Jacksonville, FL, USA.
Goodison
S
S
D000818:Animals; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D002869:Chromosome Aberrations; D002874:Chromosome Mapping; D004195:Disease Models, Animal; D023281:Genomics; D006801:Humans; D007621:Karyotyping; D009362:Neoplasm Metastasis / Q000235:genetics*; D009693:Nucleic Acid Hybridization; D011379:Prognosis
D014408:Biomarkers, Tumor